Stocks AstraZeneca PLC

More

  • S&P 500 tries to avoid a 5 session slide Tuesday, 10 Nov 2015 | 7:01 AM ET

    U.S. stock futures were lower this morning, after Wall Street's worst day since late September. The Dow went back into the red for 2015.

  • MUMBAI, Nov 10- Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said on Tuesday it had been temporarily barred by a U.S. court from selling its generic form of blockbuster heartburn drug Nexium in the United States. The order was passed by the U.S. district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion objecting to...

  • AstraZeneca lupus drug impresses in mid-stage trial Tuesday, 10 Nov 2015 | 2:00 AM ET

    LONDON, Nov 10- AstraZeneca's experimental lupus drug anifrolumab significantly cut disease activity in a mid-stage clinical trial, boosting hopes for a medicine the company believes could become a $1 billion- a-year seller. AstraZeneca's anifrolumab, which is given intravenously, is designed for patients with moderate to severe lupus and works in a...

  • ORLANDO, Nov 9- Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3- year trial of more than 7,000 patients caused a sensation in September,...

  • *JPMorgan, Bank of America, Citigroup shares strong. Nov 6- U.S. stocks ended little changed on Friday, with a rise in financials countered by a slide in utilities and other sectors, as Wall Street took the strong U.S. jobs report as evidence the Federal Reserve will soon raise interest rates. The overall market on Friday was "holding up well," Peter Jankovskis, co-chief...

  • *Unemployment rate falls to lowest since April 2008. The Labor Department's report showed nonfarm payrolls increased by 271,000 in October, beating the 180,000 expected. The unemployment rate fell to 5.0 percent, the lowest since April 2008, from 5.1 percent in September.

  • The Labor Department report showed nonfarm payrolls increased by 271,000 in October, beating the 180,000 expected. "This is without question the sort of report that will continue to keep the hike conversation for December alive and well," said Tom Porcelli, Chief U.S. Economist at RBC Capital Markets in New York.

  • *The report by the Labor Department, due at 8:30 a.m. ET, is expected to show that nonfarm payrolls increased 180,000 in October, above the 139,000 jobs per month average for August and September. **Nvidia's shares rose 10 percent to $30.50 premarket after the chipmaker's third-quarter results beat expectations. *TripAdvisor fell 9.2 percent to $75.50 after...

  • Wall Street seeks 6th winning week Friday, 6 Nov 2015 | 7:02 AM ET

  • Early movers: TIME, FB, SEAS, TAP, VC, NDLS & more Thursday, 5 Nov 2015 | 7:53 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, Nov 5- AstraZeneca lifted its full-year forecast for revenue and earnings on Thursday as Chief Executive Pascal Soriot said the group was showing resilience, despite eroding sales of some of its top-selling medicines. "Looking ahead, however, the continued performance of our growth platforms and upcoming launches will combine with our increasing...

  • LONDON, Nov 3- GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday. Britain's biggest drugmaker is trying to boost low investor expectations for its pipeline by hosting its first research and...

  • Markets to tune out Fed speakers in favor of data Friday, 30 Oct 2015 | 6:28 PM ET
    A trader works on the floor of the New York Stock Exchange on Aug. 24, 2015, in New York City.

    Markets will be laser-focused on Friday's October jobs report in the week ahead and may even look past more than a dozen scheduled Fed speeches.

  • Oct 29- Pfizer Inc, the No. 1 U.S. drugmaker, and Botox maker Allergan Plc said they were in friendly talks to create a pharmaceutical colossus but the prospect that the company would seek to avoid U.S. taxes sounded political alarm bells. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms of the...

  • Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday said they were in early, friendly talks to create the world's largest drugmaker and potentially set up Pfizer to take advantage of Ireland's lower tax rates. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms. Allergan shares jumped 8...

  • Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday said they were in early, friendly talks to create the world's largest drugmaker and potentially set up Pfizer to take advantage of Ireland's lower tax rates. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms. Allergan shares jumped 8...

  • UPDATE 2-Pfizer, Allergan say in talks on merger Thursday, 29 Oct 2015 | 10:36 AM ET

    Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday confirmed they were in preliminary, friendly talks on a potential merger, a deal that would create the world's largest drugmaker. Both Pfizer and Ireland- based Allergan said no agreement has been reached and declined to discuss any terms that might lead to such a tie-up. Allergan shares jumped 8.2...

  • Oct 29- Allergan Plc's shares soared as much as 16 percent in premarket trading on Thursday, a day after media reports that Pfizer Inc had held early talks with the Botox-maker about a deal that would create the world's biggest drugmaker. A combination of Dublin- based Allergan with New York- based Pfizer would create a $330- billion pharma giant and extend an...

  • Pfizer said to be in talks with Allergan Thursday, 29 Oct 2015 | 7:07 AM ET
    Pfizer headquarters in New York.

    Pfizer has held early talks with Allergan to discuss what could be the biggest takeover deal this year, according to media reports.

  • *Pfizer and Allergan decline to comment. A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second recent attempt to acquire a big rival, following its unsuccessful courtship last year of Anglo-Swedish pharmaceuticals group AstraZeneca Plc. Combining Allergan and Pfizer, which is worth $219 billion, would create the world's largest...